Additional Information

Description

Udenyca 6 mg/0.6 mL Syringe is a biologic medication primarily used to reduce the incidence of infection in cancer patients receiving chemotherapy. It contains the active ingredient pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim stimulates the bone marrow to produce white blood cells, specifically neutrophils, thereby helping to prevent febrile neutropenia, a condition characterized by a low white blood cell count and fever, which can be a life-threatening side effect of chemotherapy.

The medication is administered as a subcutaneous injection, typically given once per chemotherapy cycle, at least 24 hours after chemotherapy. The exact dosing schedule is determined based on the patient's treatment regimen and specific medical needs. Udenyca helps to minimize the duration of neutropenia and reduce the risk of infection in patients undergoing chemotherapy.

Common side effects include bone pain, headache, and injection site reactions, while more serious adverse effects such as splenic rupture and acute respiratory distress syndrome (ARDS) are rare but possible. Patients receiving Udenyca should be monitored for signs of these severe side effects.